Patents by Inventor Ivan ZLATEV
Ivan ZLATEV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230257745Abstract: One aspect of the present invention relates to a small circular interfering RNA (sciRNA) comprising a sense strand and an antisense strand, each of said sense and antisense strands comprising at least one nucleic acid modification, optionally wherein the sense strand has a circular or substantially circular structure. Other aspects of the invention relate a pharmaceutical composition and a method for inhibiting the expression of a target gene in a subject using the sciRNA.Type: ApplicationFiled: July 9, 2021Publication date: August 17, 2023Inventors: Hartmut JAHNS, Ivan ZLATEV, Muthiah MANOHARAN, Christopher S. THEILE
-
Patent number: 11643657Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.Type: GrantFiled: December 17, 2019Date of Patent: May 9, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
-
Publication number: 20230029227Abstract: The present invention relates, in general to agents that modulate the pharmacological activity of siRNAs. In addition, the invention relates generally to methods and systems for use in assessing the efficacy and safety of a pharmaceutical composition for use in the treatment or prophylaxis of a disease.Type: ApplicationFiled: January 25, 2022Publication date: January 26, 2023Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Ivan ZLATEV, Adam CASTORENO, Martin MAIER, Vasant JADHAV, Jae KIM, Pushkal GARG
-
Publication number: 20230016929Abstract: One aspect of the present invention relates to a compound comprising an antisense strand which is complementary to a target gene; a sense strand which is complementary to said antisense strand; and one or more lipophilic monomers, containing one or more lipophilic moieties, conjugated to one or more positions on at least one strand, optionally via a linker or carrier. Another aspect of the invention relates to a method of gene silencing, comprising administering to a cell or a subject in need thereof a therapeutically effective amount of the lipophilic monomer-conjugated compound.Type: ApplicationFiled: November 6, 2020Publication date: January 19, 2023Inventors: Jayaprakash K. NAIR, Martin A. MAIER, Juan C. SALINAS, Shigeo MATSUDA, Alexander V. KEL'IN, Scott P. LENTINI, Guo HE, Michelle H. JUNG, Justin M. PIERSON, Muthiah MANOHARAN, Dale C. GUENTHER, Ivan ZLATEV, Christopher S. THEILE, Vasant R. JADHAV, Stuart MILSTEIN, Maja JANAS, Dhrubajyoti DATTA
-
Publication number: 20220259589Abstract: The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs.Type: ApplicationFiled: August 10, 2021Publication date: August 18, 2022Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Vasant JADHAV, John MARAGANORE, Martin MAIER, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Akin AKINC, Ivan ZLATEV
-
Publication number: 20220177885Abstract: The present disclosure relates generally to cleavable linkers and uses thereof.Type: ApplicationFiled: February 10, 2022Publication date: June 9, 2022Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Jayaprakash K. NAIR, Kallanthottathil G. RAJEEV, Scott LENTINI, Christopher S. THEILE, Martin MAIER, Ivan ZLATEV
-
Publication number: 20220127604Abstract: The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs.Type: ApplicationFiled: August 10, 2021Publication date: April 28, 2022Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Vasant JADHAV, John MARAGANORE, Martin MAIER, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Akin AKINC, Ivan ZLATEV
-
Publication number: 20220106593Abstract: The present invention relates, in general to, compounds, compositions and methods useful for modulating gene expression of multiple target nucleic acids by a single chemical entity.Type: ApplicationFiled: February 22, 2021Publication date: April 7, 2022Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Vasant JADHAV, Martin MAIER, Ivan ZLATEV, Akin AKINC, Kallanthottathil G. RAJEEV, Jayaprakash K. NAIR, Pachamuthu KANDASAMY, Muthiah MANOHARAN
-
Patent number: 11286482Abstract: The present disclosure relates generally to cleavable linkers and uses thereof.Type: GrantFiled: January 18, 2018Date of Patent: March 29, 2022Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Jayaprakash K. Nair, Kallanthottathil G. Rajeev, Scott Lentini, Christopher S. Theile, Martin Maier, Ivan Zlatev
-
Patent number: 11053495Abstract: The present invention relates, in general to, compounds, compositions and methods useful for modulating gene expression of multiple target nucleic acids by a single chemical entity.Type: GrantFiled: July 15, 2016Date of Patent: July 6, 2021Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Vasant Jadhav, Martin Maier, Ivan Zlatev, Akin Akinc, Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Pachamuthu Kandasamy, Muthiah Manoharan
-
Publication number: 20210130821Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.Type: ApplicationFiled: December 17, 2019Publication date: May 6, 2021Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena ., Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
-
Publication number: 20210115444Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.Type: ApplicationFiled: September 9, 2020Publication date: April 22, 2021Inventors: Meena, David Butler, Naoki Iwamoto, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
-
Patent number: 10815482Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.Type: GrantFiled: August 22, 2018Date of Patent: October 27, 2020Assignee: WAVE LIFE SCIENCES LTD.Inventors: Meena, David Butler, Naoki Iwamoto, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
-
Patent number: 10590413Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.Type: GrantFiled: March 17, 2017Date of Patent: March 17, 2020Assignee: WAVE LIFE SCIENCES LTD.Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
-
Publication number: 20190330630Abstract: The present disclosure relates generally to cleavable linkers and uses thereof.Type: ApplicationFiled: January 18, 2018Publication date: October 31, 2019Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Jayaprakash K. NAIR, Kallanthottathil G. RAJEEV, Scott LENTINI, Christopher THEILE, Martin MAIER, Ivan ZLATEV
-
Publication number: 20190106696Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.Type: ApplicationFiled: August 22, 2018Publication date: April 11, 2019Inventors: Meena, David Butler, Naoki Iwamoto, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
-
Patent number: 10160969Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.Type: GrantFiled: January 16, 2015Date of Patent: December 25, 2018Assignee: WAVE LIFE SCIENCES LTD.Inventors: Meena, David Butler, Naoki Iwamoto, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
-
Patent number: 10131908Abstract: The present invention provides nucleosides and oligonucleotides comprising a 5? phosphate mimics of formula (IVc) or (Vc), One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleotide of formula (Ia). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.Type: GrantFiled: November 24, 2014Date of Patent: November 20, 2018Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Marija Prhavc, Ivan Zlatev
-
Patent number: 10119136Abstract: One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene in vivo. The dsRNA duplex comprises one or more 4?-modifications in one or both strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for in vivo therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.Type: GrantFiled: January 9, 2015Date of Patent: November 6, 2018Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Shigeo Matsuda, Kallanthottathil G. Rajeev, Ivan Zlatev
-
Publication number: 20180208927Abstract: The present invention relates, in general to, compounds, compositions and methods useful for modulating gene expression of multiple target nucleic acids by a single chemical entity.Type: ApplicationFiled: July 15, 2016Publication date: July 26, 2018Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Vasant JADHAV, Martin MAIER, Ivan ZLATEV, Akin AKINC, Kallanthottathil G. RAJEEV, Jayaprakash K. NAIR, Pachamuthu KANDASAMY, Muthiah MANOHARAN